The Pharmaceutical Industry in India (2026): Size, Exports, Challenges and Opportunities
The pharmaceutical industry in India is one of the largest in the world, supplying affordable medicines to more than 200 markets. It is known as the pharmacy of the world because of its strength in generic medicines, vaccines, active pharmaceutical ingredients (APIs) and contract manufacturing.
This guide explains how big the Indian pharmaceutical industry is, what it exports and where, the main challenges it faces, and the opportunities ahead, using recent, sourced data. It also covers what the industry’s growth means for importers and distributors, especially in Africa.
Key Facts at a Glance
| Indicator | Figure | Source and period |
|---|---|---|
| Size of the Indian pharma industry | About US$60 billion | Pharmexcil, April 2026 |
| Projected size by 2030 | US$130 billion | Pharmexcil, April 2026; Economic Survey 2025-26 |
| Pharma exports, FY2024-25 | US$30.47 billion (up 9.4%) | Pharmexcil handbook |
| Pharma exports, FY2025-26 | Above US$31 billion | DGCIS data, reported May 2026 |
| Pharma exports, April-June 2026 (Q1 FY27) | US$8.10 billion (up 6.8%) | Pharmexcil, August 2026 |
| Global rank by production volume | Third | Pharmexcil chairman, April 2026 |
| Global rank by export value | 11th | Economic Survey 2025-26 (PIB summary) |
| Export destinations | More than 200 markets | Pharmexcil, April 2026 |
| Share of exports to highly regulated markets | More than 60% | Pharmexcil, April 2026 |
How Big Is the Indian Pharmaceutical Industry?
The Indian pharmaceutical industry is valued at around US$60 billion, according to Pharmexcil (the Pharmaceuticals Export Promotion Council of India), and is projected to reach US$130 billion by 2030.
It is worth separating two rankings that are often mixed up. India is generally described as third in the world by volume of pharmaceutical production. By value of exports it ranks lower (11th, as summarised from the Economic Survey 2025-26), because much of what India makes is affordable generic medicine.
A Short History
- Before 1970: foreign companies dominated the Indian market and domestic competition was limited.
- 1970 onwards: the Indian Patents Act of 1970 recognised process patents rather than product patents for medicines. This helped local companies build skills in reverse-engineering and producing generics, and exports began to grow.
- 1990s: economic liberalisation encouraged Indian companies to expand abroad and invest in quality and facilities.
- 2005: an amendment to the Patents Act introduced product patents, in line with international trade rules. Indian companies adapted by strengthening R&D, regulatory skills and partnerships.
What India Makes and Exports
India’s pharmaceutical output covers several product groups:
- Generic formulations: tablets, capsules, injectables, syrups and other finished dosage forms
- APIs and bulk drugs: the active ingredients used to make medicines
- Vaccines and biologicals
- Contract and third-party manufacturing for other companies’ brands
Formulations and biologicals form the largest part of exports. In FY2024-25 drug formulations and biologicals accounted for about 75% of exports (US$22.93 billion) and bulk drugs for US$4.87 billion. In FY2025-26 formulations and biologicals contributed US$23.08 billion, about 74.2% of the total, and vaccines were the fastest-growing category at about US$1.5 billion, up 26.4%.
Where Does India Export?
The United States is India’s largest single market, accounting for about 31% of exports in April-June 2026. North America, Europe, Africa and Latin America together account for nearly 75% of exports.
Export growth has not been smooth. In March 2026 exports fell about 23% from the previous March, which industry leaders linked to US stockpiling ahead of tariffs. Even so, FY2025-26 exports crossed US$31 billion, and growth continued in Q1 FY27.
India and Africa
Africa is a major and growing destination for Indian medicines. In FY2024-25 it accounted for about 12.9% of India’s pharmaceutical exports, and exports to Africa rose about 13% in FY2025-26.
For African importers, the strengths of Indian suppliers include a wide product range, competitive pricing and manufacturers with WHO-GMP certification. Registration is handled country by country, by regulators such as NAFDAC in Nigeria, the Pharmacy and Poisons Board in Kenya and the Ghana FDA. Buyers should check that a supplier can provide a valid GMP certificate, batch Certificates of Analysis and the dossier format their regulator requires.
Key Challenges Facing the Industry
- Price pressure. Domestic price controls and global competition on generics keep margins tight.
- Trade and tariff volatility. The March 2026 export decline shows how sensitive exports can be to US tariffs and inventory cycles.
- Dependence on imported inputs. Many manufacturers rely on imported APIs and key starting materials for some products.
- Quality and regulatory compliance. Meeting GMP standards across many markets requires continuous investment in quality systems.
- Rising compliance and sustainability costs. Environmental rules, data integrity requirements and audits add cost and complexity.
- Innovation gap. The industry is strongest in generics, and moving into complex generics, biosimilars and new drugs needs higher R&D spending.
Key Opportunities
- A growing home market. Rising incomes, insurance coverage and healthcare infrastructure support demand, with the industry projected to reach US$130 billion by 2030.
- Vaccines and biologicals. These were the fastest-growing export categories in FY2025-26.
- Africa and other emerging markets. Exports to Africa, Oceania and Latin America grew faster than the overall total in FY2025-26.
- Trade agreements. The government highlights the India-UK CETA, the India-EU FTA and the EFTA agreement as opening new access for pharmaceutical exports.
- Contract and third-party manufacturing. Global and regional brands increasingly outsource manufacturing to qualified Indian plants.
- Policy support. Government programmes support domestic manufacturing of bulk drugs and medical products.
Leading Indian Pharma Companies
India’s pharmaceutical sector includes large listed companies and thousands of small and mid-sized manufacturers. Well-known names include Sun Pharma, Cipla, Dr. Reddy’s, Lupin, Zydus, Aurobindo Pharma, Divi’s Laboratories and Glenmark. Rankings change every year with revenue and market capitalisation, so check a current source before comparing companies.
What This Means for Importers and Distributors
If you plan to source medicines from India, look beyond price. Check:
- a valid manufacturing licence and WHO-GMP certificate
- the dosage forms and therapy areas the plant is approved for
- quality control, stability data and batch documentation
- regulatory support for your country’s registration process
- minimum order quantity, lead time and payment terms
For a deeper look, read our guides to choosing a pharma contract manufacturer in India and third-party pharma manufacturing in India.
About Salvavidas Pharma
Salvavidas Pharma is a WHO-GMP certified pharmaceutical manufacturer and exporter based in Surat, Gujarat, India. We work across finished dosage forms and APIs, including generics, oncology and anti-HIV/ARV products, and supply export markets in Africa and beyond.
Explore our finished formulations, contract manufacturing, regulatory services, manufacturing facility and global presence, or download our company profile.
Looking for a reliable Indian pharma supplier? Contact our export team with your product list, target country and expected volumes.
Frequently Asked Questions
How big is the pharmaceutical industry in India?
It is valued at about US$60 billion and is projected to reach US$130 billion by 2030, according to Pharmexcil. India is third in the world by production volume.
Why is India called the pharmacy of the world?
Because it produces a very large volume of affordable generic medicines, vaccines and APIs and supplies them to more than 200 markets.
How much does India export in pharmaceuticals?
Exports were US$30.47 billion in FY2024-25 and crossed US$31 billion in FY2025-26. In April-June 2026 they reached US$8.10 billion.
Which countries import the most Indian medicines?
The United States is the largest single market, followed by countries such as Brazil, the United Kingdom, the Netherlands and France in recent data. Africa as a region accounted for about 12.9% of exports in FY2024-25.
What are the biggest challenges for the Indian pharma industry?
Price pressure, trade and tariff volatility, dependence on imported inputs, strict quality and compliance requirements, and the need to invest more in complex products and R&D.
Is India’s pharma industry growing?
Yes. Exports have grown in recent years, though at a slower pace in FY2025-26 than in FY2024-25, and Q1 FY27 exports rose 6.8% year on year.
Sources
- Pharmexcil handbook (June 2025): exports FY2024-25, product and regional breakdown
- Government of India (PIB) summary of Economic Survey 2025-26: industry size, export ranking, trade agreements
- India Med Today: Indian pharma exports cross US$31 billion in FY26 (DGCIS data)
- Indian Pharma Post: India’s pharma exports rise 6.8% to US$8.1 billion in Q1 FY27 (Pharmexcil data)
- Outlook Business: pharma exports cross US$28 billion till February (PTI, April 2026)
Disclaimer
Figures are taken from the published sources above as of the dates shown and may be revised. This article is for general information and does not constitute business or investment advice.